Multidrug Resistance Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis
Conditions: Tuberculosis; Rifampicin Resistant Tuberculosis Interventions: Drug: Pretomanid; Drug: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Global Alliance for TB Drug Development (TB Alliance); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2022 Category: Research Source Type: clinical trials

Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
Condition: Tuberculosis, Multidrug-Resistant Intervention: Drug: Amikacin Sponsors: Rwanda Biomedical Centre; Institute of Tropical Medicine; World Health Organization Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2022 Category: Research Source Type: clinical trials